key: cord-0943811-cv8r9pbl authors: Roshanravan, Neda; Seif, Farhad; Ostadrahimi, Alireza; Pouraghaei, Mahboub; Ghaffari, Samad title: Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review date: 2020-06-19 journal: Arch Med Res DOI: 10.1016/j.arcmed.2020.06.012 sha: 871115d995995ff30d2a53bcd537989958a7c5fe doc_id: 943811 cord_uid: cv8r9pbl Abstract Corona Virus Disease 2019 (COVID-19) pandemic is rapidly spreading all over the world. Excessive immune responses trigger life-threatening cytokine release syndrome (CRS) which can result in overproduction of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1β with different pro-inflammatory roles. Anecdotal evidence suggests that the modulation of systemic immune responses may have a potential role in the treatment of patients with COVID-19. Given the importance of the issue and the lack of therapeutic treatment or vaccine; anti-cytokine therapy such as IL-6, TNFα and IL-1 antagonists have been suggested for the alleviation of hyper-inflammation status in these patients. In this mini-review, we addressed the inflammatory pathways of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its relationship with the host cytokine storm. Furthermore, the proposed therapeutic options to reverse hyper-inflammation in infected patients were mentioned. In December 2019, coronavirus disease 2019 (COVID-19) outbreak commenced in Wuhan, Hubei province, China and spread rapidly to other provinces in China and several countries all over the world (1) . This infectious disease has been identified by the World Health Organization (WHO) as a global pandemic. Based on the WHO declaration on January 30, 2020, the outbreak of COVID-19 is a global health emergency of international concerns due to its capability of rapid human-to-human transmission (2) . The mortality rate of COVID-19 is terribly growing worldwide. As of April 16, 2020 , this severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected a total of 2,060,927 confirmed cases with 134,354 deaths in more than 200 countries and territories (3) . SARS-CoV-2 is a novel β-coronavirus that belongs to the subfamily Orthocoronavirinae in the family of Coronaviridae, in the order of Nidovirales. The SARS-CoV-2 is an enveloped positive-sense single-stranded RNA (+ssRNA) virus with 4 major proteins in its structure, including the spike (S) protein (which mediates attachment to the host receptor and subsequent fusion of the virus and cell membrane), the membrane (M) protein, the envelope (E) protein, and the nucleocapsid (N) protein (4) . Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are other β-coronavirus widespread epidemics in 2002 and 2012, respectively (5) . Based on recent pieces of evidence, SARS-CoV-2 has approximately 79-82% similarity to human SARS-CoV genome at the nucleotide sequences. It has been supposed that the SARS-CoV-2 virus, similar to SARS CoV, uses the angiotensin-converting enzyme 2 (ACE2) as the receptor for entering host cells (6). ACE2 receptors are expressed in the membrane of various cells in the human body, including type II alveolar epithelial cells of the lung (7). Accordingly, it is expected that the bilateral diffuse alveolar injury with cytodiagnosis of myxoid fibroma exudate is the first pathological finding of COVID-19 (8). Furthermore, kidney, intestine, heart, and blood vessels are the other organs expressing ACE2 receptor, and this may describe why some patients with COVID-19 (~46%) experience renal, gastrointestinal, and cardiovascular problems (9,10). The spike glycoprotein (S) mediates virus entry via binding to the host cell's ACE2 receptor and membrane fusion (11). It is supposed that the interaction of the viral particle with specific proteins on the host cell surface and entering of the virus to human cells are the main triggers, which initiate infection and inflammatory cascade through various mechanisms with consequent release of pro-inflammatory cytokines (6,12). To the best of our knowledge the main clinical features of patients with COVID-19 consist of a) high concentration of inflammatory parameters such as C-reactive protein (CRP) and pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, tumor necrosis factor-α (TNFα), etc.; b) Infiltration of immune cells to the lung lesion mostly monocytes and macrophages; c) Destruction of the immune system owing to atrophy of spleen and lymph nodes; d) Reduction of lymphocytes (lymphopenia) in lymphoid organs; and ultimately; e) Vasculitis, hypercoagulability, and multiple organs damage (13) . The term "cytokine release syndrome" (CRS) or cytokine storm syndrome (CSS) was defined as a systemic inflammatory response, which can occur by a variety of factors, including infections and certain drugs (14) . In this review, we addressed the inflammatory pathways of SARS-CoV-2 and its relationship with the host cytokine storm. Furthermore, the proposed therapeutic options to reverse hyper-inflammation in infected patients were mentioned. The understanding of molecular mechanisms involved in this viral infection provides new insights into the more appropriate management of COVID-19. Inflammation is the immediate body's defense against infection or trauma injury; however, it can be considered a double-edged sword. Inflammation with activation of both innate and adaptive immune responses can enhance host immunity against infection, while excessive immune responses following some pathogens such as the influenza virus, trigger life-threatening CSS in the host, which can result in excessive production of pro-inflammatory cytokines and eventually, leads to death (15, 16) . Cytokines are a group of secreted proteins that are released by some cells with specific effects on the development, differentiation, and regulation of immune cells (17) . According to recent studies, SARS-CoV-2 stimulates innate and adaptive immune systems after binding to type II alveolar epithelial cells of the lung; the over-stimulated response of the immune system may cause more damage to the host cells than the SARS-CoV-2 as a foreign invader (18) . Toll-like receptors (TLRs), a subfamily of pattern recognition receptors (PRRs), can recognize "danger signals" such as SARS-CoV-2 viruses in the extracellular milieu and endosomes and mediate the inflammatory signaling cascade that leads to the activation and production of inflammatory cytokines (19) . Inflammasomes are multi-protein cytosolic molecular platforms comprised of caspase-1, Nod-like receptors (NLRs; i.e., NLRP1, NLRP3, and NLRC4) and apoptosis-associated (26) . Similarly, other reports also established the increased level of IL-6 in patients with confirmed COVID-19 pneumonia and it has been shown that the level of IL-6 has a positive correlation with the severity of the disease (4, 27, 28) . In another study, Huang C, et al. (29) reported that the plasmatic concentration of IL-2, IL-7, interferon-gamma (IFN-γ), granulocyte-colony stimulating factor (GCSF), interferon γ-induced Modulation of systemic immune responses may have a potential role in the treatment of patients with COVID-19. Given the importance of the issue and the lack of a vaccine or proven effective therapy, anti-cytokine therapy such as IL-6, TNFα and IL-1 antagonists have been suggested for the alleviation of hyper-inflammation as the main leading cause of severe adult respiratory distress syndrome (ARDS) in patients with COVID-19 (31, 32) . Importantly, some clinical findings in China have shown that Tocilizumab (a monoclonal anti-IL-6 receptor) can significantly improve oxygenation and may be considered a promising therapeutic option in patients with COVID-19 who are at the risk of cytokine storm (33) . Another small sample clinical trial in China has indicated good efficacy of Tocilizumab treatment in severe COVOD-19 patients (34) . A case report from France reported successful treatment of Covid-19-related respiratory failure using Tocilizumab in a patient with cancer (35) . According to previous studies, Tocilizumab can reduce the affinity of IL-6R to IL-6 by binding to IL-6R and soluble IL-6R, thereby inhibiting the CSS (18) . Tocilizumab as a recombinant humanized monoclonal antibody has been approved for the treatment of patients with severe CSS (36, 37) . Anakinra infusions might have significant survival benefits owing to possibly reversing the cytokine storm in patients with COVID-19 (38) . Previously, Shakoory B, et al. (39) claimed that the administration of Anakinra intravenously at a dose of 2.0 mg/kg/h for 72 h could significantly reduce the 28 d mortality in 484 patients with severe sepsis. Though the exact role of IL-1 in the pathogenesis of CSS is unclear, it seems that IL-1 receptor blockade may aid in better control of the inflammatory process. According to the previous reports, Anakinra is a biopharmaceutical drug with a wide therapeutic range, and high safety (40). Currently, Anakinra has been approved by the food and drug administration (FDA) for the treatment of a variety of auto-immune diseases, including rheumatoid arthritis as well as neonatal-onset multisystem inflammatory disease (41) . TNFα is another main cytokine in many inflammatory diseases. The elevated level of TNFα in blood and tissues of patients with COVID-19 has been indicated in previous reports (42, 43) . The potential role of anti-TNF therapy has been considered recently for reducing inflammation in COVID-19. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) Coronavirus disease 2019 (COVID-19): situation report, 72 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China Managing cytokine release syndrome associated with novel T cell-engaging therapies Targeting the "cytokine storm" for therapeutic benefit Cytokine release syndrome Cytokines and autoimmunity The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality TLR signaling pathways Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 COVID-19: consider cytokine storm syndromes and immunosuppression Tocilizumab treatment in COVID-19: a single center experience Effective treatment of severe COVID-19 patients with tocilizumab Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report Chimeric antigen receptor T cells for sustained remissions in leukemia Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) Continuous Intravenous Anakinra Infusion to Calm the Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed Correlation analysis between disease severity and inflammationrelated parameters in patients with COVID-19 pneumonia Regulation of cytokines, cytokine inhibitors, and acutephase proteins following anti-TNF-α therapy in rheumatoid arthritis Figure Legend Figure 1. A proposed pathway for inducing cytokine storm following SARS-Cov-2 infection After entering to type II alveolar epithelial cells of the lungs, SARS CoV-2 triggers life-threatening cytokine release in the host, which can result in excessive levels of pro-inflammatory cytokines production including IL-6, TNF-α and IL-1β. Type II AEC: type II alveolar epithelial cells; RBC: red blood cells; IL: interleukin; TNF α: tumor necrosis factor α; IFN-γ: interferon-gamma, GCSF: granulocyte-colony stimulating factor, IP-10: interferon γ-induced protein; MCP1: monocyte chemoattractant protein 1; MIP: macrophage inflammatory proteins; Th: T helper NAME FOR TOP OF PAGES: Roshanravan • The outbreak of COVID-19 (coronavirus) has been identified by the World Health Organization as a global pandemic • There is an urgent need to identify safe and effective drugs or potential adjuvant therapy in this regard Inflammatory cytokines blockade proposed to be a novel therapeutic approach to reverse hyper-inflammatory status in COVID-19 infected patients The authors would like to thank the Cardiovascular Research Center of Tabriz University of Medical Sciences.